RATIONALE: Cystic fibrosis lung disease is characterized by accumulation of apoptotic neutrophils, indicating impaired clearance of dying cells. Pseudomonas aeruginosa, the principal microbial pathogen in cystic fibrosis, manipulates apoptosis induction via production of toxic metabolites. Whether these metabolites, particularly pyocyanin, can also modulate apoptotic cell engulfment is unknown. OBJECTIVES: To assess the effects of pyocyanin on apoptotic cell engulfment by macrophages in vitro and in vivo and to investigate potential mechanisms of the observed effects. METHODS: Human monocyte-derived macrophages were treated with pyocyanin before challenge with apoptotic neutrophils, apoptotic Jurkat cells, or latex beads, and phagocytosis was assessed by light microscopy and flow cytometry. Effects of pyocyanin production on apoptotic cell clearance in vivo were assessed in a murine model, comparing infection by wild-type or pyocyanin-deficient P. aeruginosa. Oxidant production was investigated using fluorescent probes and pharmacologic inhibition and Rho GTPase signaling by immunoblotting and inhibitor studies. MEASUREMENTS AND MAIN RESULTS: Pyocyanin treatment impaired macrophage engulfment of apoptotic cells in vitro, without inducing significant macrophage apoptosis, whereas latex bead uptake was preserved. Macrophage ingestion of apoptotic cells was reduced and late apoptotic/necrotic cells were increased in mice infected with pyocyanin-producing P. aeruginosa compared with the pyocyanin-deficient strain. Inhibition of apoptotic cell uptake involved intracellular generation of reactive oxygen species (ROS) and effects on Rho GTPase signaling. Antioxidants or blockade of Rho signaling substantially restored apoptotic cell engulfment. CONCLUSIONS: These studies demonstrate that P. aeruginosa can manipulate the inflammatory microenvironment through inhibition of apoptotic cell engulfment, and suggest potential strategies to limit pulmonary inflammation in cystic fibrosis.
RATIONALE: Cystic fibrosis lung disease is characterized by accumulation of apoptotic neutrophils, indicating impaired clearance of dying cells. Pseudomonas aeruginosa, the principal microbial pathogen in cystic fibrosis, manipulates apoptosis induction via production of toxic metabolites. Whether these metabolites, particularly pyocyanin, can also modulate apoptotic cell engulfment is unknown. OBJECTIVES: To assess the effects of pyocyanin on apoptotic cell engulfment by macrophages in vitro and in vivo and to investigate potential mechanisms of the observed effects. METHODS: Human monocyte-derived macrophages were treated with pyocyanin before challenge with apoptotic neutrophils, apoptotic Jurkat cells, or latex beads, and phagocytosis was assessed by light microscopy and flow cytometry. Effects of pyocyanin production on apoptotic cell clearance in vivo were assessed in a murine model, comparing infection by wild-type or pyocyanin-deficient P. aeruginosa. Oxidant production was investigated using fluorescent probes and pharmacologic inhibition and Rho GTPase signaling by immunoblotting and inhibitor studies. MEASUREMENTS AND MAIN RESULTS: Pyocyanin treatment impaired macrophage engulfment of apoptotic cells in vitro, without inducing significant macrophage apoptosis, whereas latex bead uptake was preserved. Macrophage ingestion of apoptotic cells was reduced and late apoptotic/necrotic cells were increased in mice infected with pyocyanin-producing P. aeruginosa compared with the pyocyanin-deficient strain. Inhibition of apoptotic cell uptake involved intracellular generation of reactive oxygen species (ROS) and effects on Rho GTPase signaling. Antioxidants or blockade of Rho signaling substantially restored apoptotic cell engulfment. CONCLUSIONS: These studies demonstrate that P. aeruginosa can manipulate the inflammatory microenvironment through inhibition of apoptotic cell engulfment, and suggest potential strategies to limit pulmonary inflammation in cystic fibrosis.
Authors: Konosuke Morimoto; William J Janssen; Michael B Fessler; Kathleen A McPhillips; Valeria M Borges; Russell P Bowler; Yi-Qun Xiao; Jennifer A Kench; Peter M Henson; R William Vandivier Journal: J Immunol Date: 2006-06-15 Impact factor: 5.422
Authors: Lynne R Usher; Roderick A Lawson; Ian Geary; Christopher J Taylor; Colin D Bingle; Graham W Taylor; Moira K B Whyte Journal: J Immunol Date: 2002-02-15 Impact factor: 5.422
Authors: Ralph M Vicari; Bernard Chaitman; Deborah Keefe; William B Smith; Steven G Chrysant; Melvin J Tonkon; Neville Bittar; Robert J Weiss; Hugo Morales-Ballejo; Udho Thadani Journal: J Am Coll Cardiol Date: 2005-10-19 Impact factor: 24.094
Authors: L T McGrath; P Mallon; L Dowey; B Silke; E McClean; M McDonnell; A Devine; S Copeland; S Elborn Journal: Thorax Date: 1999-06 Impact factor: 9.139
Authors: Rabindra Tirouvanziam; Carol K Conrad; Teodoro Bottiglieri; Leonore A Herzenberg; Richard B Moss; Leonard A Herzenberg Journal: Proc Natl Acad Sci U S A Date: 2006-03-13 Impact factor: 11.205
Authors: P Birrer; N G McElvaney; A Rüdeberg; C W Sommer; S Liechti-Gallati; R Kraemer; R Hubbard; R G Crystal Journal: Am J Respir Crit Care Med Date: 1994-07 Impact factor: 21.405
Authors: K F Ferri; E Jacotot; J Blanco; J A Esté; N Zamzami; S A Susin; Z Xie; G Brothers; J C Reed; J M Penninger; G Kroemer Journal: J Exp Med Date: 2000-10-16 Impact factor: 14.307
Authors: Maher Y Abdalla; Traci Hoke; Javier Seravalli; Barbara L Switzer; Melissa Bavitz; Jill D Fliege; Peter J Murphy; Bradley E Britigan Journal: Infect Immun Date: 2017-08-18 Impact factor: 3.441
Authors: S Jovic; H M Linge; M M Shikhagaie; A I Olin; L Lannefors; J S Erjefält; M Mörgelin; A Egesten Journal: Mucosal Immunol Date: 2015-05-20 Impact factor: 7.313